Medicare Entitlement, LIS, Dual Eligibility, and Parts A-D
Medicare eligibility and benefit variables that distinguish entitlement reason, Parts A/B/C/D coverage, low-income subsidy status, and Medicare-Medicaid dual eligibility; these determine observable claims, cost sharing, and cohort eligibility in Medicare RWE.
In plain language
Medicare data only make sense if you know what the person was actually enrolled in at each time. Part A/B fee-for-service, Medicare Advantage, Part D drug coverage, LIS, dual eligibility, and entitlement reason all change what the data can see.
Medicare RWE depends on eligibility state, not just age. A beneficiary can have Part A, Part B, Part C Medicare Advantage enrollment, Part D drug coverage, low-income subsidy status, Medicaid dual eligibility, disability entitlement, ESRD entitlement, or changing combinations over time. These variables determine which claims are observable, which services are covered, and whether pharmacy exposure, medical utilization, and cost sharing can be interpreted.
Analysts should treat Medicare coverage as time-varying. A person can move from FFS to Medicare Advantage, gain or lose Part D, enter a dual-eligible state, or change LIS status. A continuous-enrollment rule that ignores benefit coverage can create false drug gaps, missing medical events, or unobservable outcomes. Reason for entitlement also matters: aged entitlement, disability, and ESRD populations differ clinically and operationally.
Medicare has official Parts A, B, C, and D. There is no standard Medicare Part E benefit. If a dataset or stakeholder says "Part E," clarify whether they mean Extra Help/LIS, Medigap/supplemental coverage, employer wraparound, or a local variable.
Pros, cons, and trade-offs
Month-level Medicare eligibility variables make claims analyses defensible because they distinguish coverage from observability. They reveal when pharmacy fills, medical claims, cost sharing, or MA encounter data can be interpreted. The trade-off is complexity: person-time must be split by month, benefit channel, and enrollment state before exposure and outcome construction. Collapsing everything to one baseline enrollment flag is easier, but it can create false nonadherence, false outcome absence, and biased cost denominators.
When to use
Use full entitlement, A/B/C/D, LIS, dual, and reason-for-entitlement variables whenever a Medicare analysis depends on complete medical claims, Part D pharmacy exposure, cost-sharing interpretation, MA/FFS channel, disability or ESRD entitlement, or socioeconomic confounding. Use them before cohort construction, not as a late Table 1 decoration.
When NOT to use - and when it is actively misleading
Do not treat a beneficiary as observable just because they are "enrolled in Medicare." Do not assume Part D exposure capture without Part D coverage, or FFS medical outcome capture during Medicare Advantage months unless encounter data are proven fit for purpose. It is actively misleading to use "Part E" as if it were an official Medicare benefit category.
Index definitions
Source-backed definitions and variants for the index or checklist family.
| name | definition | source | use | notes |
|---|---|---|---|---|
| Part A | Hospital insurance, including inpatient hospital, skilled nursing facility, hospice, and some home health coverage. | Medicare.gov Parts of Medicare | Determines inpatient/hospital benefit eligibility in Original Medicare. | Entitlement alone is not the same as observed complete FFS claims if MA enrollment intervenes. |
| Part B | Medical insurance, including physician, outpatient, preventive, and certain drug/administration services. | Medicare.gov Parts of Medicare | Determines professional and outpatient medical claim observability in FFS. | Buy-and-bill drugs may appear under Part B rather than Part D. |
| Part C | Medicare Advantage plan coverage offered by private plans approved by Medicare. | Medicare.gov Parts of Medicare | Identifies periods where FFS claims may be incomplete or replaced by encounter data. | Treat MA as a distinct observability state. |
| Part D | Prescription drug coverage for Medicare beneficiaries. | Medicare.gov Parts of Medicare | Required for complete retail pharmacy exposure and adherence measurement in Medicare. | LIS affects cost sharing and can affect adherence and treatment choice. |
| Part E | Not an official Medicare benefit part. | Medicare.gov Parts of Medicare | Clarification item when stakeholders use informal shorthand. | Often confusion with Extra Help/LIS, Medigap, employer supplemental coverage, or local variables. |
| LIS / Extra Help | Program that helps eligible beneficiaries pay Medicare drug coverage costs. | CMS Low Income Subsidy | Cost-sharing covariate, subgroup, and proxy for socioeconomic status in Part D analyses. | Time-varying monthly status should be used when available. |
| Dual eligibility | Monthly Medicare-Medicaid dual status variable identifying full or partial dual eligibility categories. | ResDAC dual eligibility code | Eligibility covariate, subgroup, and data-completeness/cost-sharing flag. | Full and partial dual categories should not be collapsed without considering the research question. |
| Reason for entitlement | Current or original reason Medicare entitlement was established, such as age, disability, ESRD, or combinations. | ResDAC reason for entitlement code | Cohort eligibility, stratification, and confounding control. | Original and current reason can differ; choose intentionally. |
Worked example
Scenario
A Part D adherence study follows beneficiaries monthly. One patient has Parts A/B/D and LIS in January-June, becomes full dual eligible in July, and switches to Medicare Advantage in October. The study needs complete pharmacy capture and observable medical events.
Dataset
Month-level Medicare eligibility panel.
| month | part_a | part_b | part_c_ma | part_d | lis | dual_status | analytic_use |
|---|---|---|---|---|---|---|---|
| 2024-01 | True | True | True | True | none | observable FFS medical + Part D pharmacy | |
| 2024-07 | True | True | True | True | full dual | observable; dual/LIS covariates update | |
| 2024-10 | True | True | True | True | True | full dual | MA observability flag; FFS outcome capture no longer assumed |
Steps
Build person-month eligibility before exposure episodes or outcomes.
Require Part D for pharmacy adherence denominators.
Require A/B FFS observability for medical outcomes unless fit-for-purpose MA encounter data are available.
Update LIS and dual status monthly rather than treating them as baseline constants.
Result
January-September can support FFS medical plus Part D analyses; October onward requires MA-specific handling or censoring under a documented strategy.